Nefrocarnit (Levocarnitine)

Levocarnitine functions as a carrier that transports long‑chain fatty acids into mitochondria. Inside the organelle it forms acyl‑carnitine complexes, enabling β‑oxidation of fatty acids to generate ATP. This process is essential for tissues with high energy demand, such as cardiac and skeletal muscle, and helps correct metabolic imbalances caused by carnitine deficiency.

The appropriate dose of Nefrocarnit is determined by the prescribing clinician based on the patient’s age, weight, severity of deficiency, and clinical response. Dosage regimens are individualized and may be adjusted during therapy; patients should follow the specific instructions provided by their healthcare professional.

Safety data for levocarnitine in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss potential risks and benefits with the patient.

To place an order, submit an enquiry on the Nefrocarnit product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any cold‑chain requirements—and assistance with import documentation.

Nefrocarnit provides levocarnitine in an intravenous formulation, which allows rapid restoration of plasma carnitine levels compared with oral L‑carnitine preparations that have lower bioavailability. Intravenous delivery is preferred in acute settings or when oral absorption is compromised, whereas oral supplements are typically used for long‑term maintenance.

Nefrocarnit should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Prior to administration, inspect the solution for particulate matter or discoloration. Keep the product in its original packaging until use to maintain stability and sterility.

Nefrocarnit is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate should be controlled according to the prescribing information, typically administered slowly to reduce the risk of infusion‑related reactions. Dosage adjustments may be required based on patient response and clinical monitoring.

The most serious adverse events reported with intravenous levocarnitine include anaphylactic reactions, seizures, and cardiac arrhythmias. These events are rare but require immediate medical intervention. Patients should be monitored closely during and after infusion, and any signs of severe hypersensitivity or neurologic changes should prompt urgent evaluation.

Nefrocarnit is contraindicated in patients with known hypersensitivity to levocarnitine or any component of the formulation. Caution is advised for individuals with severe renal or hepatic impairment, uncontrolled cardiac disease, or those receiving medications that may interact significantly, such as valproic acid or high‑dose phenobarbital. Clinical judgment should guide use in these populations.